Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 14/20 | 0.42 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1761591 | 0.99 | TNKS (0.42) | TNKSPRMT5ADRA2AADRA2BADRA2C | |
| SCHEMBL1761667 | 0.80 | DRD4 (0.49) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL1761623 | 0.78 | CHRNA7 (0.60) | — | |
| Hydrochloric Acid SCHEMBL1761864 | 0.77 | CHRNA7 (0.58) | — | |
| SCHEMBL260898 | 0.76 | HTR3A (0.64) | — | |
| SCHEMBL260289 | 0.76 | HTR3A (0.64) | — | |
| SCHEMBL261296 | 0.76 | HTR3A (0.64) | — | |
| SCHEMBL1761414 | 0.74 | P2RX7 (0.55) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL2132196 | 0.73 | TNKS (0.46) | TNKSPRMT5METTL3METTL14KIT | |
| SCHEMBL1761896 | 0.71 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | claimed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | claimed |
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| US-7897766-B2 | [3H]-(S,S)-2,2-dimethyl-5-(6-phenyl-pyridazin-3-yl)-5-aza-2-azonia-bicyclo[2.2.1]heptane, iodide; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, mild cognitive impairment, age-associated memory impairment | ABBOTT LABORATORIES (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118301-A1 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | TNKS 2855/4885PRMT5 94/4885ADRA2A 61/4885 |
| US-20080234308-A2 | Amino-Aza-Adamantane Derivatives and Methods of Use | CHRNA7, CHRNA5, CHRNA1 | TNKS 2855/4885PRMT5 94/4885ADRA2A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.